* Ekso Bionics Holdings Inc EKSO.OQ reported a quarterly
adjusted loss of 13 cents per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of -31 cents. The mean expectation of two analysts
for the quarter was for a loss of 13 cents per share. Wall
Street expected results to range from -15 cents to -11 cents per
share.
* Revenue rose 5.3% to $4.95 million from a year ago;
analysts
expected $5.17 million.
* Ekso Bionics Holdings Inc's reported EPS for the quarter
was a
loss of 13 cents.
* The company reported a quarterly loss of $2.42 million.
* Ekso Bionics Holdings Inc shares had risen by 23.2% this
quarter and lost 48.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Ekso Bionics
Holdings Inc is $6.25
This summary was machine generated from LSEG data July 29 at
10:35 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.13 -0.13 Met
Mar. 31 2024 -0.16 -0.20 Missed
Dec. 31 2023 -0.11 -0.22 Missed
Sep. 30 2023 -0.31 -0.24 Beat